Search
Propylthiouracil
go.drugbank.com/drugs/DB00550ApprovedA thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharma...
Queuine
go.drugbank.com/drugs/DB14732ExperimentalNutraceuticalAll eukaryotic organisms, including humans, transform queuine to queuosine by placing it in the wobble position (anticodon) of several tRNAs including aspartic acid, asparagine, histidine, and tyrosine
TAS-102
go.drugbank.com/drugs/DB08937InvestigationalTrifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.
Malacidin A
go.drugbank.com/drugs/DB14051ExperimentalMalacidin A, along with [DB14052], is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria [A33312].
Seliciclib
go.drugbank.com/drugs/DB06195InvestigationalDeveloped by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation
Candoxatrilat
go.drugbank.com/drugs/DB11623ExperimentalA dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy
Sifalimumab
go.drugbank.com/drugs/DB12773InvestigationalSifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.
Malacidin B
go.drugbank.com/drugs/DB14052ExperimentalMalacidin B, along with [DB14051], is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria [A33312].
PMI-001
go.drugbank.com/drugs/DB05730ExperimentalPMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.
LU-31130
go.drugbank.com/drugs/DB05828ExperimentalLU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.